Literature DB >> 20432243

VEGF-A expression in osteoclasts is regulated by NF-kappaB induction of HIF-1alpha.

Diana P Trebec-Reynolds1, Irina Voronov, Johan N M Heersche, Morris F Manolson.   

Abstract

Large osteoclasts (10+ nuclei), predominant in rheumatoid arthritis and periodontal disease, have higher expression of proteases and activating receptors and also have increased resorptive activity when compared to small (2-5 nuclei) osteoclasts. We hypothesized that large and small osteoclasts activate different signaling pathways. A Signal Transduction Pathway Finder Array was used to compare gene expression of large and small osteoclasts in RAW 264.7-derived osteoclasts. Expression of vascular endothelial growth factor A (Vegfa) was higher in large osteoclasts and this result was confirmed by RT-PCR. RT-PCR further showed that RANKL treatment of RAW cells induced Vegfa expression in a time-dependent manner. Moreover, VEGF-A secretion in conditioned media was also increased in cultures with a higher proportion of large osteoclasts. To investigate the mechanism of Vegfa induction, specific inhibitors for the transcription factors NF-kappaB, AP-1, NFATc1, and HIF-1 were used. Dimethyl bisphenol A, the HIF-1alpha inhibitor, decreased Vegfa mRNA expression, whereas blocking NF-kappaB, AP-1, and NFATc1 had no effect. Furthermore, the NF-kappaB inhibitor gliotoxin inhibited Hif1alpha mRNA expression. In conclusion, VEGF-A gene and protein expression are elevated in large osteoclasts compared to small osteoclasts and this increase is regulated by HIF-1. In turn, Hif1alpha mRNA levels are induced by RANKL-mediated activation of NF-kappaB. These findings reveal further differences in signaling between large and small osteoclasts and thereby identify novel therapeutic targets for highly resorptive osteoclasts in inflammatory bone loss. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432243     DOI: 10.1002/jcb.22542

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  17 in total

1.  Pericyte-endothelial cell interaction: a survival mechanism for the tumor vasculature.

Authors:  Sharmila Chatterjee; Ulhas P Naik
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

2.  Targeting vascular endothelial growth factor ameliorates PMMA-particles induced inflammatory osteolysis in murine calvaria.

Authors:  Wahid Abu-Amer; Manoj Arra; John C F Clohisy; Yousef Abu-Amer; Gaurav Swarnkar
Journal:  Bone       Date:  2019-03-21       Impact factor: 4.398

Review 3.  Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.

Authors:  Richard J Lee; Matthew R Smith
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

Review 4.  Novel insights into redox system and the mechanism of redox regulation.

Authors:  Xin Wang; Chunxu Hai
Journal:  Mol Biol Rep       Date:  2016-06-02       Impact factor: 2.316

Review 5.  Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis.

Authors:  Ursula Fearon; Mary Canavan; Monika Biniecka; Douglas J Veale
Journal:  Nat Rev Rheumatol       Date:  2016-05-26       Impact factor: 20.543

Review 6.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

7.  Identification of differential DNA methylation alterations of ovarian cancer in peripheral whole blood based on within-sample relative methylation orderings.

Authors:  Hongdong Li; Fengle Jiang; Yuhui Du; Na Li; Zhihong Chen; Hao Cai; You Guo; Guini Hong
Journal:  Epigenetics       Date:  2021-03-22       Impact factor: 4.528

8.  Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.

Authors:  Sudha Visvanathan; Mahboob U Rahman; Edward Keystone; Mark Genovese; Lars Klareskog; Elizabeth Hsia; Michael Mack; Jacqui Buchanan; Michael Elashoff; Carrie Wagner
Journal:  Arthritis Res Ther       Date:  2010-11-17       Impact factor: 5.156

9.  Gliotoxin potentiates osteoblast differentiation by inhibiting nuclear factor-κB signaling.

Authors:  Guangye Wang; Xiaohai Zhang; Baoqing Yu; Ke Ren
Journal:  Mol Med Rep       Date:  2015-03-20       Impact factor: 2.952

10.  High-throughput screen of natural product libraries for hsp90 inhibitors.

Authors:  Jason Davenport; Maurie Balch; Lakshmi Galam; Antwan Girgis; Jessica Hall; Brian S J Blagg; Robert L Matts
Journal:  Biology (Basel)       Date:  2014-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.